Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. Its product pipeline include Piclidenoson, Namodenoson, and CF602. The company was founded by Pnina Fishman and Ilan Cohn on September 11, 1994 and is headquartered in Petach-Tikva, Israel.
相关临床试验
36
14 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1994
进行中（未招募）
12
33.3%
已完成
14
38.9%
尚未招募
2
5.6%
招募中
5
13.9%
终止
1
2.8%
撤回
2
5.6%
暂无批准数据
- Can-Fite BioPharma received Brazilian patent protection for using A3 adenosine receptor agonists to treat sexual dysfunction, expanding its intellectual property portfolio in Latin America's largest pharmaceutical market. - The patent is based on preclinical and clinical data suggesting A3 adenosine receptor activation can modulate key signaling mechanisms involved in erectile and sexual function through vascular, inflammatory, and metabolic pathways. - This intellectual property milestone strengthens Can-Fite's position for potential partnering and commercialization opportunities while validating the therapeutic versatility of its A3AR agonist platform across multiple medical conditions.
- Can-Fite BioPharma is conducting pivotal Phase III trials for Namodenoson in advanced hepatocellular carcinoma patients with Child-Pugh B7 liver function, addressing a significant unmet medical need with no approved therapies. - The company is simultaneously running a Phase III study of Piclidenoson for psoriasis treatment, with both programs expected to report interim data in Q4 2026 and Q2 2026 respectively. - Namodenoson demonstrates multi-indication potential with ongoing Phase IIb studies in MASH and Phase IIa trials in pancreatic cancer, following positive Phase IIa results showing anti-inflammatory, anti-steatotic, and anti-fibrotic effects.
- Can-Fite BioPharma will participate in BioFIT 2025 to advance veterinary partnerships for Namodenoson, its Phase III anti-cancer drug candidate with demonstrated strong anti-tumor activity and excellent safety profile. - The company aims to explore collaborations with major animal health companies including Elanco Animal Health and Zoetis to bring Namodenoson into veterinary oncology development. - Veterinary oncology represents a significant market opportunity projected to reach $3.1 billion by 2030, building on Can-Fite's successful $325 million partnership with Vetbiolix for Piclidenoson. - Namodenoson has shown complete response in human liver cancer patients and is currently being evaluated in Phase III liver cancer and Phase II pancreatic cancer trials.
- Can-Fite BioPharma received patent allowance in Brazil for CF602, an A3 adenosine receptor modulator targeting erectile dysfunction in diabetic patients and non-responders to current treatments. - The drug addresses a significant unmet need, as approximately 35% of patients in the $3.2 billion erectile dysfunction market do not respond to standard PDE5 inhibitors like Viagra and Cialis. - Preclinical studies in diabetic rat models demonstrated full erectile recovery with a single CF602 dose, showing restored muscle collagen ratio and improved endothelial function. - CF602's unique mechanism avoids receptor desensitization and can be administered both orally and topically, potentially offering treatment options for 16 million diabetic men in the U.S. who are contraindicated for current ED medications.
- Can-Fite BioPharma announced a patient with advanced hepatocellular carcinoma treated with Namodenoson has achieved 9 years of cancer-free survival with complete response. - The patient from a completed Phase II study continues treatment through compassionate use and meets complete responder criteria with normal liver function and quality of life. - Can-Fite is currently enrolling patients in a pivotal Phase III trial for Namodenoson as second or third-line treatment for advanced HCC across Israel, Europe, and the U.S. - Namodenoson has received Orphan Drug status from FDA and EMA, plus Fast Track designation from FDA for hepatocellular carcinoma treatment.
- Can-Fite BioPharma announced complete resolution of esophageal varices in a decompensated liver cirrhosis patient treated with Namodenoson under compassionate use, confirmed by endoscopic evaluation. - Esophageal varices are severe complications of advanced liver disease with high bleeding risk, and their resolution in decompensated cirrhosis is uncommon, suggesting potential disease-modifying effects. - Namodenoson is currently in Phase III trials for hepatocellular carcinoma and Phase IIb trials for MASH, targeting the A3 adenosine receptor with high selectivity. - The finding provides supplementary evidence for Namodenoson's broader therapeutic potential in a market projected to reach $15 billion by 2030.
- Can-Fite BioPharma completed a $5 million public offering with potential for an additional $10 million through warrant exercises to fund clinical trials and R&D activities. - The company's lead drug candidate Piclidenoson recently reported Phase 3 topline results for psoriasis and has commenced a pivotal Phase 3 trial. - Namodenoson, Can-Fite's liver drug, is currently being evaluated in Phase III trials for hepatocellular carcinoma and has received FDA Fast Track Designation. - The company's drug pipeline has demonstrated an excellent safety profile across over 1,600 patients in clinical studies to date.
- UCLA researchers led by Dr. S. Thomas Carmichael demonstrated that Piclidenoson restored tissue integrity and behavioral function in a vascular dementia mouse model with focal ischemia. - The study addresses a significant unmet medical need, as vascular dementia is the second most common cause of dementia with no FDA-approved therapies currently available. - Piclidenoson, a highly selective A3 adenosine receptor agonist, has already shown compelling safety in hundreds of psoriasis patients and could potentially capture a large share of the $6 billion vascular dementia market. - Can-Fite's Chief Scientific Officer noted that a first-in-class agent providing neuroprotection and improved vascular health would fill a significant treatment gap in this growing market.
• Can-Fite BioPharma has secured $3 million through a registered direct offering of 2.5 million American Depositary Shares priced at $1.20 per ADS, with the transaction expected to close by April 15, 2025. • The biotech company plans to allocate the proceeds toward advancing its pipeline of small-molecule drugs, including Piclidenoson for psoriasis, Namodenoson for liver cancer and MASH, and CF602 for erectile dysfunction. • Namodenoson has received Orphan Drug Designation in both the U.S. and Europe, as well as Fast Track Designation from the FDA as a second-line treatment for hepatocellular carcinoma.
- Can-Fite BioPharma has initiated a pivotal Phase 3 clinical trial for Piclidenoson, an oral drug targeting moderate to severe plaque psoriasis, with protocols approved by both FDA and EMA regulatory authorities. - The randomized, double-blind study will evaluate 3mg twice-daily oral dosing, measuring efficacy through PASI 75 scores and Static Physician's Global Assessment at Week 16, with patient enrollment beginning in Europe before expanding to North America. - Piclidenoson works by inhibiting inflammatory cytokines IL-17 and IL-23 while inducing apoptosis in affected skin cells, positioning it as a potential key player in the psoriasis market projected to reach $30 billion by 2030.
